EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Application Value of Plasma-Derived Exosomal miR-1269a Detection in Diagnosing Non-Small Cell Carcinoma

Jingping Ran, Yuanxue Zhu, Jianqiao Zhang

Acta Poloniae Pharmaceutica - Drug Research · 23.07.2026 · 84 (2) · 209-217

DOI: 10.32383/appdr/224810 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Poloniae Pharmaceutica - Drug Research, online erschienen am 23.07.2026. Verfasst von Jingping Ran und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The aim of this study was to explore the diagnostic value of plasma-derived exosome miR-1269a detection in non-small cell lung cancer (NSCLC). We preselected miR 1269a because it is consistently upregulated and functionally oncogenic in NSCLC—acting through FOXO1 and p53/PI3K–AKT pathways and has shown promising diagnostic performance as a circulating/exosomal marker in prior studies. Fifty NSCLC patients who visited Hebei University Affiliated Hospital from February 2022 to August 2022 were selected as the NSCLC group, and 30 healthy individuals undergoing physical examination were selected as the healthy control group. The levels of plasma-derived exosomal miR-1269a, cytokeratin 19 fragment (CYFRA21-1), and carcinoembryonic antigen (CEA) in peripheral blood were detected and compared between the groups. The levels of plasma-derived exosomal miR-1269a, CYFRA21-1, and CEA in NSCLC patients at different stages were compared. The clinical diagnostic value of miR-1269a, CYFRA21-1, and CEA for NSCLC was compared using ROC curves. The levels of plasma-derived exosomal miR-1269a, CYFRA21-1, and CEA in the NSCLC group were higher than those in the healthy control group. The levels of plasma-derived exosomal miR-1269a, CYFRA21-1, and CEA in the NSCLC group increased with the stage of NSCLC. The ROC curve showed that plasma-derived exosomal miR-1269a had a higher diagnostic value for NSCLC compared to CYFRA21-1 and CEA. miR-1269a is elevated in peripheral blood of NSCLC patients and has a high diagnostic value for NSCLC. These findings suggest that plasma-derived exosomal miR-1269a may serve as a promising noninvasive biomarker for the diagnosis of NSCLC.

Zitieren

APA

Ran, J., Zhu, Y., & Zhang, J. (2026). Application Value of Plasma-Derived Exosomal miR-1269a Detection in Diagnosing Non-Small Cell Carcinoma. Acta Poloniae Pharmaceutica - Drug Research, 84(2), 209-217. https://doi.org/10.32383/appdr/224810

Vancouver

Ran J, Zhu Y, Zhang J. Application Value of Plasma-Derived Exosomal miR-1269a Detection in Diagnosing Non-Small Cell Carcinoma. Acta Poloniae Pharmaceutica - Drug Research. 2026;84(2):209-217. doi:10.32383/appdr/224810

BibTeX
@article{Ran2026,
  author = {Ran, Jingping and Zhu, Yuanxue and Zhang, Jianqiao},
  title = {Application Value of Plasma-Derived Exosomal miR-1269a Detection in Diagnosing Non-Small Cell Carcinoma},
  journal = {Acta Poloniae Pharmaceutica - Drug Research},
  year = {2026},
  volume = {84},
  number = {2},
  pages = {209--217},
  doi = {10.32383/appdr/224810}
}
Kostenlos starten →